Efthymios Deliargyris - 08 Aug 2025 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Reporting relationship: Chief Medical Officer
Issuer ticker: CTSO
Reported as of: 08 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2025, 19:34:26 UTC
Prior SEC filing: 22 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Peter J. Mariani attorney-in-fact Efthymios Deliargyris

Key filing fact

Efthymios Deliargyris filed Form 4 for Cytosorbents Corp (CTSO) on 08 Aug 2025.

Key facts

This page summarizes Efthymios Deliargyris's Form 4 filing for Cytosorbents Corp (CTSO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Aug 2025, 19:34.

Change

Previous filing in this sequence was filed on 22 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001751617 Primary reporting owner

Deliargyris Efthymios

Relationship: Chief Medical Officer
Address: C/O CYTOSORBENTS CORPORATION, 305 COLLEGE ROAD EAST, PRINCETON
Signature: /s/ Peter J. Mariani attorney-in-fact Efthymios Deliargyris
Signature date: 08 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CTSO transaction

Common Stock

Award

Transaction value: $0
Shares: +70,000
Change %: +17%
Price: $0.000000
Shares after: 473,025
Date: 08 Aug 2025
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CTSO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +95,000
Change %
Price: $0.000000
Shares after: 95,000
Date: 08 Aug 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 95,000
Exercise price: $1.00
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs") which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

Footnote F2

Includes: (ii) the following RSUs that will be settled into Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 120,000 RSUs granted on April 9, 2020 and (b) 55,000 RSUs granted on August 10, 2022;

Footnote F3

(continued from footnote 2) (iii) the following RSUs, which vest in equal parts on the first year anniversary of the date of grant and the second year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will settle into shares of Common Stock of the Company upon vesting: 61,000 RSUs granted on April 2, 2024 and of which 30,500 remain unvested as of the date hereof; and

Footnote F4

(continued from footnote 3) (iv) 197,525 shares of Common Stock owned by the reporting person.

Footnote F5

These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first year anniversary of the date of grant, one-fourth of the award on the second year anniversary of the date of grant, and one-fourth of the award on the third year anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.

SEC remarks

Exhibit 24.1 Power of Attorney